Kornimate/medical-research-clean huggingface dataset:
effect of meal on portal and esophagus variceal pressure

Conditions: Cirrhosis; Esophageal Varices

Summary: the reason why esophagus varices suddenly rupture and start to bleed is unclear. food intake increase the hepatic blood flow and the portal pressure, but it is yet unknown if there is also an increase in variceal pressure. the aim of this study is to evaluate the efficacy of a meal on variceal pressure with a non invasive endoscopic measurement device, and compare it with portal pressure.


Eligibility criteria:
inclusion criteria: * large esophageal varices exclusion criteria: * treatment with beta-blocking agents * respiratory diseases that contradict endoscopy * gastric-retention * former gastric resection * resent sclerotherapy or former banding

Keywords: cirrhosis, portal hypertension, esophageal varices, meal
surgical versus medical treatment of acromegaly

Conditions: Acromegaly

Summary: evaluate biochemical differences in acromegalic patients treated with surgery versus somatostatin analogues (sms) (after surgery or alone). hypothesis: treatment modality exhibit different biochemical responses in acromegaly.


Eligibility criteria:
inclusion criteria: * acromegaly diagnosis * treated with somatostatin analogues or surgery * in treatment control exclusion criteria: * treatment with gh-antagonist * never treated * not in treatment control

Keywords: acromegaly somatostatin analogues treatment
antibiotic prophylaxis for tevar

Conditions: Aortic Dissection; Aortic Diseases; Aortic Aneurysm, Thoracic; Coarctation of Aorta; Hematoma; Aorta

Summary: the infection rate of thoracic endovascular aortic repair (tevar) is unknown due to a lack of epidemiological data. the rate currently available comes from researches conducted decades ago, when open surgery was the standard of care. because of the potentially fatal consequences of a stent graft infection in the thoracic aorta, the investigators tend to prescribe antibiotic prophylaxis for at least three days. in this study, the investigators are going to collect data on patients receiving tevar in the past five years and provide the following information: a. the infection rate (magic classification), b. the rate of fever, c. the results of the lab tests, such as the wbc count and c-reaction protein. d. risk factors associated with infection and fever.


Eligibility criteria:
inclusion criteria: 1. diagnosed with thoracic aortic diseases 2. received tevar exclusion criteria: 1. suspected infectious aortic disease, such as a mycotic aneurysm. 2. tevar combined with open surgery 3. antibiotics have been used more than 24 hours before the operation 4. combined with immune deficiency disease or using hormone or immunosuppressant； 5. the treatment is for the complications of tevar, such as endoleak 6. endovascular aortic repair for abdominal aortic disease 7. history of open aortic surgery or heart surgery. 8. revascularization of visceral arteries during the tevar

Keywords: antibiotic prophylaxis tevar fever magic classification
how does basic body awareness therapy effect pain coping strategies in postmenopausal women?

Conditions: Low Back Pain; Neck Pain; Menopause

Summary: exercise interventions are deemed essential for the effective management of patients with pain. various therapy methods have been shown in the literature for pain and coping with pain. however, there is no study investigating the effectiveness of basic body awareness therapy in pain and coping with pain. in this respect, our study will contribute to the literature. the aim of our study is to compare the effectiveness of basic body awareness therapy and therapeutic exercises on pain coping strategies of postmenopausal women.

the patients will be randomly assigned into three groups: therapeutic exercise (te) group, therapeutic exercise+basic body awareness (te+bbat) group, and control group. each group will be treated for 12 weeks. individuals will be evaluated in detail at the beginning and end of the study. the follow-up assessments of the study will be done 3 months after the conclusion of the treatments. physical and sociodemographic characteristics will be evaluated by dedicated form. the body awareness of the participants will be evaluated body awareness questionnaire (baq) developed by shields, mallory \& simon in 1989. the pain levels of the pmw will be measured with the short form mcgill pain questionnaire. pain coping strategies of pmw will be assessed with pain coping inventory (pci). the oswestry low back pain disability index will be used for evaluating the disability level caused by low back pain. the neck disability index will be used for evaluating the disability level caused by neck pain.

Eligibility criteria:
inclusion criteria: participants should have; * chronic lower back or neck pain lasting at least six months * gone through the menopausal transition naturally within the last year * not received a physiotherapy approach for pain management in the last six months * be able to read and write in turkish. exclusion criteria: * presence of significant neurological disorders * presence of serious mental and psychological disorder

Keywords: postmenopausal women basic body awareness therapy pain coping
topical sgx302 for mild-to-moderate psoriasis

Conditions: Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris

Summary: to evaluate sgx302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.


Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application. * have a static investigator global assessment (iga)/psoriasis area and severity index (pasi) of disease severity of mild or moderate on the body (trunk and/or limbs). * have lesions involving 2-30% of the body (trunk and/or limbs). for subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%. exclusion criteria: * use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study. * received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study. * received systemic psoriasis therapy within 4 weeks prior to the beginning of the study. * received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.

Keywords: hypericin
change of fatigue and physical fitness in hospitalized hematology patients

Conditions: Acute Leukemia

Summary: the purposes of this study are to (1) explore the severity of symptom of leukemia patients experienced before and after chemotherapy in hospital, (2) investigate the trajectories of the fatigue and physical fitness, and their related factors, and (3) the correlation between fatigue and physical fitness

cancer-related fatigue (crf) is one of the common distressed symptoms that leukemia patients experienced during the period of chemotherapy. exercise is the most effective non-pharmacologic treatment but inpatients refuse to do exercise in clinical settings in taiwan. decreased physical activity may increase the intensity of fatigue and degenerate the physical fitness; however, there is no study to explore the trajectories of fatigue and physical fitness for leukemia patient during hospitalization. therefore, the purposes of this study are to (1) explore the severity of symptom of leukemia patients experienced before and after chemotherapy in hospital, (2) investigate the trajectories of the fatigue and physical fitness, and their related factors, and (3) the correlation between fatigue and physical fitness. a longitudinal designed study will be conducted to recruit the leukemia patients in a medical center in taipei. eligible patients are those will be going to receive chemotherapy and in hospital at least one week. time periods for data collection will be in the first 48 hours after hospitalization (t0) and the 48 hours before the patient discharged (t1). a set of structured questionnaire will be used to collected data including the background information form, the fatigue symptom inventory, the cancer fatigue scale, the symptom severity scale, and the hospital anxiety and depression scale. patients will be received physical fitness test including the 6-minute walking test, grip strength, and 30-second chair stand test. the descriptive statistics will be used to analyze the severity of symptom distress, fatigue, and the change of physical fitness, and the inferential statistics was used to analyze the correlation of the symptom, fatigue, and physical fitness. besides, generalized estimating equations (gee) will be used to analysis the average of population change of fatigue and physical fitness.

Eligibility criteria:
inclusion criteria: * acute leukemia patients with first complete remission status * aged above 20 * be going to receive chemotherapy and in hospital at least one week. * those who willing to participate in the research exclusion criteria: * physician consider the patient was not suitable * patients' limbs can not move * patients' conscious was unclear during hospitalization * patient with pain of joint and can't do 30-second chair stand test and 6-minute walking test

Keywords: acute leukemia, chemotherapy, cancer-related fatigue, physical fitness
study of amd3100 (plerixafor) and rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)

Summary: the purpose of this research study is to determine if plerixafor can make cll/sll (chronic lymphocytic leukemia/ small lymphocytic lymphoma) cells more sensitive to being killed by rituximab, an anti-cancer drug that is commonly used in treating cll and sll. in this study, plerixafor will be added to standard treatment with rituximab. subjects will be monitored to see how well they tolerate the use of these drugs together and how well they work to treat the leukemia. the primary objective is to determine the maximum tolerated dose (mtd) of plerixafor when combined with rituximab as treatment for previously treated patients with cll or sll.


Eligibility criteria:
inclusion criteria: * females of child bearing potential must agree to abstain from sexual activity or to use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period or be surgically sterile. males must agree to abstain from sexual activity or agree to utilize a medically approved contraception method during treatment and for 3 months after the treatment period or be surgically sterile. * diagnosis of cll or sll, relapsed from at least one prior therapy. * cll/sll cells expressing cd20 documented during screening. * eastern cooperative oncology group (ecog) performance status of ≤2. * life expectancy of at least 12 weeks. * serum creatinine ≤2.0 mg/dl. * total bilirubin ≤2.0 mg/dl. * alt (alanine aminotransferase) and ast (aspartate aminotransaminase) ≤2 times the upper limit of normal (uln); for patients with liver involvement of cll/sll disease, this limit is increased to ≤5 times the uln. * at the time of enrollment, patients must be \>4 weeks since major surgery, radiotherapy, chemotherapy (\>6 weeks for some chemotherapies), immunotherapy, biotherapy/targeted or investigational therapies and recovered from the toxicity of prior treatment to ≤ grade 1. exclusion criteria: * white blood cells (wbc) \>250 x 10\^9 cells/l. * disease refractory to rituximab therapy- defined as a failure to respond to prior rituximab-containing regimen. * women who are breastfeeding. * active viral hepatitis. * active infection or treatment with antimicrobial or antiviral therapy within 1 week of enrollment with the exception of prophylactic therapy. * history of prior allergic reaction to plerixafor or rituximab. * significant lung disease. * serious cardiac disease such as a history of sustained ventricular arrhythmia, uncontrolled and serious congestive heart failure (chf), angina, acute coronary syndrome, or myocardial infarction within 6 months of enrollment or other significant medical or psychosocial conditions that warrants exclusion.

Keywords: amd3100 rituximab chronic lymphocytic leukemia cll small lymphocytic lymphoma sll
a study to evaluate the long-term safety and efficacy of deucravacitinib in participants with crohn's disease or ulcerative colitis

Conditions: Crohn Disease; Ulcerative Colitis

Summary: the purpose of this study is to evaluate the long-term safety and efficacy of deucravacitinib in participants who have previously been enrolled in a deucravacitinib phase 2 study for moderate to severe crohn's disease or moderate to severe ulcerative colitis.


Eligibility criteria:
inclusion criteria: • previously completed open-label extension treatment in one of the parent crohn's disease or ulcerative colitis studies exclusion criteria: * women who are pregnant or breastfeeding * current colonic adenomas or dysplasia diagnosed at the endoscopy performed at the end of treatment visit of the parent study or past confirmed colonic dysplasia in the parent study that has not been eradicated other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986165 crohn colitis crohn disease crohn iliocolitis inflammatory bowel disease ulcerative colitis deucravacitinib
impact of active breathing exercises on respiratory rhythm disorders in stroke patients

Conditions: Stroke

Summary: the goal of this clinical trial is to explore the effect of active breathing exercises in stroke patients with respiratory rhythm disorder. patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. on this basis, the observation group will be given active breathing exercises. researchers will compare dysphagia of two groups.

a growing body of literature indicates the existence of a highly stable, coordinative relation between respiration and oropharyngeal swallowing in healthy adults. the goal of this clinical trial is to explore the effect of active breathing exercises in stroke patients with respiratory rhythm disorder. patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. on this basis, the observation group will be given active breathing exercises. researchers will compare dysphagia of two groups.

Eligibility criteria:
inclusion criteria: * diagnosed with respiratory rhythm disorder * age ≥ 18 years; * meeting the diagnostic criteria of stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * transferred out within three weeks of hospitalization in the neurology department. exclusion criteria: * complicated with other neurological diseases; * tracheostomy tube plugged; * unfeasible to the support of parenteral nutrition; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
weight gain in surgically treated adult-onset craniopharyngioma

Conditions: Adult-onset Craniopharyngioma; Postoperative Weight Gain

Summary: the aim of the study was to describe postoperative weight change in adults undergoing surgery for craniopharyngioma and identify preoperative factors associated with it.

morbid obesity, intractable weight gain due to hypothalamic damage, is a common and troubling complication in patients undergoing surgery for craniopharyngioma combined or not with radiotherapy, with an incidence of 23\~62% in pediatric patients. it has a major negative impact on metabolic and cardiovascular health and quality of life in long-term survivors. identifying patients at higher risks for developing postoperative weight gain is of great importance in preventing obesity and taking early actions in this population. though a lot of previous studies have been made in pediatric patients and several factors, such as hypothalamic involvement, higher body mass index (bmi) standard deviation score (sds) at diagnosis, age at diagnosis and hydrocephalus requiring a shunt, have been identified as risk factors for postoperative weight gain, data on this important morbidity in adult-onset patients are sparse, especially in chinese population. therefore, the investigators are going to undertake a retrospective evaluation of postoperative weight change in adult-onset patients undergoing surgery for craniopharyngioma and identify preoperative factors associated with it.

Eligibility criteria:
inclusion criteria: adult-onset, aged 18 years or more; pathologically confirmed craniopharyngioma; primary surgery performed at our hospital; at least 3 months of follow-up including body weight measurement; ambulatory (since lack of ambulation may predispose to weight gain); not receiving supraphysiologic doses of glucocorticoid (e.g. hydrocortisone, prednisone, or dexamethasone to exceed 12mg/m2•d hydrocortisone equivalent) for more than 2 months after tumor therapy. exclusion criteria: childhood-onset, \<18 years old; inconsistent pathology; without follow-up records in the investigators' institution.
a study of avastin (bevacizumab) in combination with standard therapy in patients with metastatic renal cell cancer.

Conditions: Renal Cell Cancer

Summary: this single arm study will assess the efficacy and safety of avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer. patients will receive avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3 times weekly (3 mio iu sc escalating to 18 mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks. the anticipated time on study treatment is until tumor progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * metastatic renal cell cancer of predominantly clear cell type; * \>=1 measurable lesion. exclusion criteria: * prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for metastatic renal cell cancer; * ongoing or recent need for full therapeutic dose of anticoagulants or chronic daily treatment with aspirin (\>325mg/day); * clinically significant cardiovascular disease.
docetaxel in head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: primary objective: * phase ii: to determine the best treatment scheme (tpf vs. pf). * phase iii: to compare the time to progression and the treatment failure at the 3 arms. secondary objectives: * to evaluate the safety at the 3 arms. * to compare the progression , overall survival and locoregional control at the 3 arms.


Eligibility criteria:
inclusion criteria: * head and neck cancer locally advanced (oral cavity, oropharynx, hypopharynx or larynx) but without evident metastasis. * inoperable tumor after revision by a multidisciplinary oncology team. * proved epidermoid carcinoma. * ecog = 0-1 * good hematologic function (i.e, hemoglobin \> 10 g/dl, ...) * good hepatologic function * good renal function exclusion criteria: * pregnant or breast-feeding women. potential child-bearing women should use an effective conceptive method and should have a negative pregnancy test at least the week before entering the study. * nasopharynx, nasal cavity and paranasal sinusitis will be excluded * previous chemotherapeutic or radiotherapeutic treatment for this disease. * previous or current neoplasms in other locations, except in situ cervicouterine cancer properly treated or basal cell or squamous cell carcinoma * symptomatic peripheral neuropathy * other clinical severe diseases * concomitant treatment with corticoids within 6 months prior to inclusion. * concomitant treatment with any other neoplastic therapy * previous treatment for current disease. * loss of weight greater than 10% within the last 3 months. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
safety and efficacy of rasagiline in restless legs syndrome

Conditions: Restless Legs Syndrome

Summary: the purpose of this study is to find out if rasagiline improves rls symptoms. we also want to make sure rasagiline is safe to give people with rls.

the primary objective is to determine if rasagiline, at a dosage of 1mg/day, is non-futile for the treatment of rls, as measured by the international rls study group rating scale (irls). the primary outcome variable will be the change in irls from baseline to week 12. the secondary objectives are to determine if rasagiline, at a dosage of 1mg/day, is safe and well-tolerated in participants with rls. also, to determine if rasagiline improves measures of global clinical change, sleep quality, excessive sleepiness, quality of life, or depressive symptoms.

Eligibility criteria:
inclusion criteria: * men and women at least 18 years of age, capable of providing informed consent * diagnosed with idiopathic rls, defined as meeting the international rls study group diagnostic criteria without evidence for secondary causes of rls * moderate or severe symptoms, defined as a score of 15 or greater on the international rls study group rating scale (irls) * not currently receiving treatment for rls. a 30-day washout period will be required for participants on dopamine agonists or other therapies. stable doses of iron supplementation will be allowed * on a stable dose of the following antidepressants, for at least 30 days prior to baseline visit: * amitriptyline, up to 50mg/day * trazodone, up to 100mg/day * citalopram, up to 20mg/day * escitalopram, up to 10mg/day * paroxetine, up to 30mg/day * sertraline, up to 100mg/day * female subjects must not be of childbearing potential or must agree to use of contraception for duration of study exclusion criteria: * signs consistent with a secondary cause of rls: * history of initial unresponsiveness to dopaminergic rls treatment despite adequate dose of initial therapy * use of another mao inhibitor within 30 days of baseline visit * allergy or adverse reaction to rasagiline * prior adverse reaction to tyramine-containing foods * use of meperidine or other opiates within 30 days of the baseline visit * use of benzodiazepines within 30 days of the baseline visit * use of antidepressants, including tcas, ssris, and snris, except for those permitted as listed above * use of other drugs or supplements contraindicated with rasagiline, including st. john's wort, mirtazapine, cyclobenzaprine, dextromethorphan, cold products that contain ephedrine, pseudoephedrine * scheduled to undergo elective surgery during the course of the study * active medical or psychiatric illness that requires changes to treatment during the course of the study or jeopardize the subject's ability to remain in the study

Keywords: restless legs syndrome rasagiline futility